Myriad gains gene testing rights in dispute with OncorMed
This article was originally published in Clinica
Myriad will be the only company in the US providing genetic testing for the breast and ovarian cancer genes BRCA1 and BRCA2, following an early settlement with OncorMed in their legal dispute over patent rights. OncorMed will withdraw from testing services for the BRCA1&2 genes and hand over the business to Myriad for an undisclosed fee.
You may also be interested in...
As sector awaits its aducanumab filing with bated breath, Biogen invests again in early stage neuroscience.
In case you missed it: catch up with snippets from interviews with industry leaders recently published by In Vivo.
While good clinical practice inspectors in the UK and the US collaborate on matters of common interest, they say that mutual recognition is simply not possible.